Premium
Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis
Author(s) -
SastreGarriga Jaume,
Reverter Juan Carlos,
Font Josep,
Tintoré Mar,
Espinosa Gerard,
Montalban Xavier
Publication year - 2001
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.81
Subject(s) - multiple sclerosis , medicine , anticardiolipin antibodies , antiphospholipid syndrome , antibody , gynecology , immunology
Recent works claiming that primary antiphospholipid syndrome (PAPS) cannot be clinically distinguished from multiple sclerosis (MS) recommend that MS patients be screened for anticardiolipin antibodies (ACA). In this study 296 randomly selected patients with MS and clinically isolated syndromes and 51 healthy controls were analyzed; ACA, anti‐β 2 ‐glycoprotein I, or antiprothrombin was found in 6 patients. No predominance of any kind of clinical manifestations and no cardinal manifestations of PAPS were found in these patients. ACA tests should be performed only when a suspicion of PAPS is raised and atypical clinical presentation for MS is found. Ann Neurol 2001;49:408–411